The biotech scorecard for the third quarter: 15 stock-moving events to watch 35.2%
STAT - By Adam Feuerstein - 7/1/2026, 8:30 AM
Attempt to Sell a Product or Service 56.5% - Appeal to Authority 25.5% - Negativity Bias 20.9%
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter: Amylyx Pharmaceuticals: Results from the Phase 3 LUCIDITY study of avexitide in post-bariatric hypoglycemia, a rare metabolic condition that causes severe drops in blood sugar. Biogen: In May, the company announced results from a... more